GlucoModicum, a company transforming glucose monitoring with proprietary needle-free magnetohydrodynamic (MHD) technology, today provides an update on the clinical performance, product development and commercialization pathway of Talisman, the Company’s needle-free continuous glucose monitor (CGM).

GlucoModicum，一家使用专有无针磁流体动力学（MHD）技术改造血糖监测的公司，今天提供了Talisman（该公司的无针连续血糖监测仪（CGM））临床性能，产品开发和商业化途径的最新信息。

Talisman is a wearable CGM that uses MHD technology to extract interstitial fluid (ISF) from the skin without the use of needles. By integrating ultra-sensitive and low-cost biosensors, Talisman enables continuous, painless, and accurate monitoring of glucose levels. Clinical Performance and manufacturing Data from an ongoing Clinical Performance Study (FIMEA-K485) of Talisman, recently presented at the World Congress of Diabetes Technology and Therapeutics in Kochi, India, confirms a strong correlation to blood glucose values (currently, N>100 individual tests).

Talisman是一种可穿戴的CGM，它使用MHD技术从皮肤中提取间质液（ISF），无需使用针头。通过集成超灵敏和低成本的生物传感器，Talisman能够连续，无痛和准确地监测血糖水平。Talisman正在进行的临床表现研究（FIMEA-K485）的临床表现和制造数据最近在印度高知的世界糖尿病技术和治疗大会上发表，证实了与血糖值的强相关性（目前，N>100个个体测试）。

The study, which commenced in 2023, will recruit up to 500 participants including patients with Type 2 diabetes and healthy volunteers and is authorized and monitored by the Finnish Medicines Agency (FIMEA) under EU regulation. CLINICAL PERFORMANCE STUDY (FIMEA-K485)ANALYSIS CORRELATION Talisman yields strong correlation to reference blood glucose measurements in clinical performance studies.The study involv.

该研究于2023年开始，将招募多达500名参与者，包括2型糖尿病患者和健康志愿者，并由芬兰药品管理局（FIMEA）根据欧盟法规授权和监测。临床表现研究（FIMEA-K485）分析相关性护身符与临床表现研究中的参考血糖测量值具有很强的相关性。这项研究涉及。